BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2026)

BioXcel Therapeutics' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 105.13% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 105.13% YoY), while the FY2025 annual figure was $1.8 million, down 73.01% from the prior year.
• Other Non-Current Liabilities was $6.7 million for Q1 2026 at BioXcel Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $21.2 million in Q1 2024 to a low of $1.8 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $4.6 million across 5 years, with a median of $2.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 724.48% in 2024, then slumped 84.57% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $2.3 million in 2022, then dropped by 18.69% to $1.9 million in 2023, then surged by 248.19% to $6.6 million in 2024, then tumbled by 73.01% to $1.8 million in 2025, then surged by 275.2% to $6.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.7 million (Q1 2026), $1.8 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.